News > Remdesivir price slashed by 25-70%

Remdesivir price slashed by 25-70%

As reports of shortages and black-marketing of antiviral Remdesivir come in from across the country, the Centre intervened to make the injectable more affordable for patients. Seven companies licensed to make the drug in India have “voluntarily lowered” their prices per 100mg/vial, in the range of 25-70 per cent.

The companies include Cadila Healthcare, Syngene International, Dr Reddy’s Laboratories, Cipla, Mylan, Jubilant Generics and Hetero Healthcare.